| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5698914 | Clinical Oncology | 2015 | 6 Pages |
Abstract
HDPRT was well tolerated and provided a high rate of local control in a clinically localised castration-resistant prostate cancer population. Although prostate cancer remained the most frequent cause of death, some patients had extended survival without evidence of disease progression.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
R. White, R. Khor, M. Bressel, G. Duchesne, S. Williams, P. Bowden, K. Tai, F. Foroudi,